Security-first AI for pharma

Stage: Live

Confidential-computing infrastructure for sensitive AI workloads processing GxP data. Claude, ChatGPT and Gemini see your GxP data in plaintext; ColdVault keeps it encrypted end-to-end, including during inference itself: not a policy promise, a hardware guarantee. When your policy requires the GPUs in your own cloud account, under your full control, we deploy ColdVault on your cloud GPUs and operate it.

Stage: Live

GlassHood is AI monitoring with dashboards, for business and IT alike. It connects to a running integration pipeline or other complex system — today a solution on Google Cloud, read from Azure — and shows where the whole system and each of its components stand, live. Rules and anomaly detection raise alerts from the measurements, and every 3 hours an AI review reads each component's logs and raises its own alarms, labelled as found by the AI review. A short AI overview says in plain words how the whole system is doing and what needs attention, and each component has its own. Business owners and IT teams look at the same dashboard, and nothing they do there changes the monitored system.

Stage: Live

AI test execution that reads existing test documents and navigates UIs autonomously. Recorded-script test automation breaks when the UI changes — and pharma UIs change often. Test teams either rewrite scripts continuously or fall back to manual testing. TestRobin adapts as the UI changes, produces audit-ready evidence reports, and doesn't require testers to code. Mixed UI + API testing; designed against ALCOA+, Annex 11, and 21 CFR Part 11 electronic-evidence requirements.

Stage: Piloting

BatchGuard checks manufacturing against its procedures. It reads the drug substance and drug product recipes and the batch records they produce, and checks every record and every field against your SOPs automatically, so reviewers start from what it flags. It does this during manufacturing, so a batch with a problem can be stopped early instead of being finished at full cost, and again after manufacturing, in the review before release.